SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-006207 to PepGen Inc. (PEPG) (CIK 0001835597) (PEPG)

PepGen Inc. (PEPG) (CIK 0001835597)
Date: June 9, 2023 · CIK: 0001835597 · Accession: 0000000000-23-006207

AI Filing Summary & Sentiment

File numbers found in text: 333-272378

Date
June 9, 2023
Author
Not clearly detected
Form
UPLOAD
Company
PepGen Inc. (PEPG) (CIK 0001835597)

Letter

United States securities and exchange commission logo June 9, 2023 James McArthur, Ph.D. President and Chief Executive Officer PepGen Inc. 321 Harrison Avenue, 8th Floor Boston, Massachusetts 02118 Re:PepGen Inc. Registration Statement on Form S-3 Filed June 2, 2023 File No. 333-272378 Dear James McArthur: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James Xu, Esq.

Show Raw Text
United States securities and exchange commission logo
June 9, 2023
James McArthur, Ph.D.
President and Chief Executive Officer
PepGen Inc.
321 Harrison Avenue, 8th Floor
Boston, Massachusetts 02118
Re:PepGen Inc.
Registration Statement on Form S-3
Filed June 2, 2023
File No. 333-272378
Dear James McArthur:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       James Xu, Esq.